Abstract
Prion diseases are associated with the structural conversion of prion protein (PrP) to a β-sheet-rich aggregate, PrPSc. Previous studies have indicated that a reduction of the disulfide bond linking C179 and C214 of PrP yields an amyloidlike β-rich aggregate in vitro. To gain mechanistic insights into the reduction-induced aggregation, here I characterized how disulfide bond reduction modulates the protein folding/misfolding landscape of PrP, by examining 1) the equilibrium stabilities of the native (N) and aggregated states relative to the unfolded (U) state, 2) the transition barrier separating the U and aggregated states, and 3) the final structure of amyloidlike misfolded aggregates. Kinetic and thermodynamic experiments revealed that disulfide bond reduction decreases the equilibrium stabilities of both the N and aggregated states by ∼3 kcal/mol, without changing either the amyloidlike aggregate structure, at least at the secondary structural level, or the transition barrier of aggregation. Therefore, disulfide bond reduction modulates the protein folding/misfolding landscape by entropically stabilizing disordered states, including the U and transition state of aggregation. This also indicates that the equilibrium stability of the N state, but not the transition barrier of aggregation, is the dominant factor determining the reduction-induced aggregation of PrP.
Introduction
Prion diseases have been associated with the structural conversion of cellular prion proteins (PrP) to an amyloidlike β-rich aggregate, PrPSc (1). PrP contains two cysteine residues at the positions of 179 and 214 (Fig. 1 A) (2). Previous in vitro studies have shown that the redox state of the disulfide bond linking the two cysteine residues is crucial for determining the amyloidogenic propensity of PrP (3, 4, 5, 6, 7, 8, 9, 10). Although it remains elusive whether the in vivo conversion of PrP to PrPSc requires the breakage or shuffling of the disulfide bond (11, 12, 13, 14), a reduction of the disulfide bond has been shown to decrease the thermal stability of PrP and trigger the formation of amyloidlike β-rich aggregates in vitro (3, 4, 5, 6, 7, 8, 9, 10). In addition, the redox state of disulfide bonds has been closely associated with amyloid formation in various other systems, including insulin (15, 16, 17, 18), tau (19, 20), lysozyme (21, 22), and β2-microglobulin (23) (reviewed by Li et al. (24)). Therefore, it is important to elucidate how the redox state of the disulfide bond is linked to PrP aggregation in vitro.
To understand the role of the disulfide bond in PrP aggregation, I first considered a protein folding/misfolding landscape involving native, unfolded, and amyloid states (Fig. 1 B), and then deduced potential thermodynamic and kinetic mechanisms by which disulfide bond reduction affects the overall rate of protein aggregation. Here, at least three mechanisms are possible: disulfide bond reduction can affect the reaction pathway of protein aggregation to create an alternative pathway with a low free-energy barrier (mechanism I), decrease the equilibrium stability of the native state (ΔGN−U) (mechanism II), or decrease the height of the kinetic barrier separating the monomeric and amyloid states of the protein (ΔG‡−U) (mechanism III) (as further detailed in the Results and Discussion).
Although a general link between disulfide bond reduction and protein aggregation has been well described in a variety of systems (24), very few studies have investigated the underlying thermodynamic and kinetic mechanisms. Typically, in the case of globular proteins such as PrP, disulfide bond reduction is regarded as accelerating protein aggregation by decreasing ΔGN−U (i.e., mechanism II) without full consideration of the folding/misfolding landscape. However, because each of three separate mechanisms could potentially contribute to the overall rate of protein aggregation (Fig. 1 B), no firm conclusion can be drawn without comprehensive understanding of the folding/misfolding landscape. Therefore, in this study, I initially examined how disulfide bond reduction modulates the folding/misfolding landscape of PrP by testing the above-described three mechanisms, and then discussed which mechanism is primarily responsible for the reduction-induced aggregation of PrP.
Materials and Methods
Amyloid formation
Amyloid fibrils were prepared from recombinant C-terminal fragments of human PrP (residues 124–230) according to a protocol to be published elsewhere. Briefly, a 250-μM protein solution containing 6 M guanidine hydrochloride (GuHCl) and 10 mM Tris-HCl (pH 8) was initially incubated for 1 h at 37°C in the presence or absence of 5 mM (5 mM Tris(2-carboxyethyl)phosphine, TCEP) to cleave the disulfide bond and remove any pre-existing aggregates. This solution was subsequently diluted to a final concentration of 25 μM in 25 mM HEPES buffer (pH 7.4) containing 0.02% NaN3, and 2 or 3 M GuHCl, with or without 5 mM TCEP. The reaction mixture was rotated at 1000 RPM and 37°C, and amyloid fibril assembly were monitored by change in ThT fluorescence at 485 nm (excitation wavelength of 445 nm) in aliquots of the reaction mixtures collected at various time points. The time courses of ThT fluorescence were fitted to a sigmoidal equation to estimate the lag time (tlag) of amyloid formation:
Solubility and stability studies for monomeric PrP
A 250-μM solution of protein was initially incubated under the reducing condition as described above, diluted to a final concentration of 10 or 25 μM in 5 mM HEPES buffer (pH 7.4) containing various concentrations of GuHCl with or without 1 mM TCEP, and incubated for 1 h at 37°C. The reaction mixture was then centrifuged at 62,900 × g for 30 min to remove insoluble aggregates, and the protein concentration in the soluble fraction (i.e., supernatant) was determined by the UV absorbance analysis (ε280 = 16,640 cm−1M−1). Soluble proteins with concentrations ≥1 μM in the supernatant were subsequently subjected to far-UV CD according to a previously published protocol (25).
Ellman reaction
To determine the redox states of amyloid fibrils, 200 μL of the amyloid solution was centrifuged at 62,900 × g for 30 min, and the resulting pellet was washed twice with cooled acidic buffer (pH 4, 20 mM sodium acetate) to remove residual reducing agents. The pellet was then resuspended with 100 μL of a denaturing buffer (pH 4, 20 mM sodium acetate and 6 M guanidine thiocyanate) and incubated at 37°C for 30 min to dissociate the amyloid fibrils into consecutive monomers. Undissociated amyloid fibrils were removed by centrifugation at 62,900 × g for 30 min at 37°C. The protein concentration of a 90 μL aliquot of the resulting supernatant supplemented with 10 μL of 1 M Tris-HCl buffer (pH 8) was determined by UV absorbance at 280 nm. The protein concentration in the supernatant (29.0 ± 2.6 and 45.9 ± 7.1 μM for oxidized and reduced proteins, respectively) suggested that 58 and 91% of the total input were recovered from oxidized and reduced amyloid fibrils, respectively. The protein solution was immediately supplemented with 1 μL of 20 mg/mL 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) in DMSO (equivalent to 50 mM), and incubated at room temperature and in the dark for 3 min. Finally, the absorbance at 412 nm was measured to determine the free –SH concentration using the Ellman method (ε = 13,700 M−1cm−1) (26). The number of free –SH groups per protein molecule was determined by dividing the free –SH concentration by the protein concentration. DTNB was purchased from Nacalai Tesque (Cat. No. 14101-21; Kyoto, Japan) and dissolved with DMSO just before use.
Structural analyses of amyloid fibrils
TEM, Fourier-transform infrared (FTIR), and proteinase-K digestion were performed using standard procedures for which the details will be published elsewhere.
GuHCl-unfolding experiment
The GuHCl-unfolding curve for oxidized PrP monomer was fitted to a two-state unfolding model:
The best fit values were as follows: −3.09 kcal/mol for ΔG, −1.68 kcal/mol M for m, −14162 degrees−1 cm2 dmol−1 for ni, −2945 degrees−1 cm2 dmol−1 for ui, and 282 degrees−1 cm2 dmol−1/M for us.
For the analysis of amyloid fibrils, a solution containing amyloid fibrils (25 μM in monomer equivalent units) was diluted 10-fold in a buffer containing 5 mM HEPES (pH 7.4), various concentrations of GuHCl (0–8.7 M) and 0 or 1 mM TCEP. The resulting solution was incubated at 37°C for 24 h and subsequently diluted fivefold with a ThT buffer [pH 8, 62.5 mM Tris-HCl, 6.25 μM ThT, and various concentration of GuHCl (0–2.0 M)] to adjust the final GuHCl concentration to 1.6 M. This dilution step is of importance, because ThT fluorescence strongly depends on the GuHCl concentration (27). Within 1 min after dilution, ThT fluorescence of the solution was measured using the above-described procedure. The GuHCl-unfolding curves were analyzed using a linear polymerization model proposed by Narimoto et al. (28):
where s represents the ThT-fluorescence per mass concentration of amyloid fibrils. The best fit values [ΔG (kcal/mol), m (kcal/mol M), and s (a.u./μM)] were as follows: −5.95, −1.14, and 0.28 for oxidized amyloid fibrils, −2.90, −0.98, and 0.32 for reduced amyloid fibrils. [M]0 was fixed to 2.5 μM.
Results and Discussion
Reducing the disulfide bond of PrP
The C-terminal domain of human PrP with an intact disulfide bond was expressed and purified according to a previously published protocol (25). The presence of the disulfide bond was previously confirmed using analytical reverse-phase HPLC and solution NMR (data not shown). To examine the role of this disulfide bond in amyloid formation, the protein was initially reduced by 1-h incubation at 37°C in the presence of a reducing agent (TCEP) and denaturant (GuHCl) at pH 8. Consistent with previous studies (5, 6), the reduced PrP exhibited a high propensity to form amorphous aggregates when diluted in a denaturant-free buffer at pH 7.4. Under these conditions, no PrP was detected in the soluble fraction after centrifugation at 62,900 × g for 30 min (Fig. 2 A).
Many studies of amyloid formation have used moderate concentrations of GuHCl to facilitate this reaction by destabilizing the native structure of oxidized PrP (25, 29, 30, 31, 32, 33). As amorphous aggregate formation observed in reduced PrP might compete with amyloid formation (34), I similarly applied a moderate concentration of GuHCl to dissolve these undesirable amorphous aggregates into soluble monomers (Fig. 2 A). Reduced PrP gradually appeared in the soluble fraction, with increasing concentrations of GuHCl from 0 to 1.5 M, and, above 2 M, the protein was fully recovered in the soluble fraction. I therefore used GuHCl at concentrations exceeding 2 M in the following evaluations of amyloid formation kinetics.
Disulfide bond reduction accelerates amyloid formation at 2 M GuHCl
I initially sought to examine the effect of disulfide bond reduction on amyloid formation at 2 M GuHCl. To this end, a reaction mixture containing either oxidized or reduced soluble PrP was agitated to initiate rapid amyloid formation, and the progress of the reaction was monitored by changes in the thioflavin T (ThT) fluorescence. As shown in Fig. 2 B, both forms of protein exhibited increases in ThT fluorescence after 4–10 h of lag phase, consistent with the typical formation kinetics of amyloid fibrils. Transmission electron micrographs of the final reaction products (Fig. 2 C) demonstrated that both oxidized and reduced samples exhibited the typical morphological characteristics of amyloid fibrils, where linear fibrillar aggregates were predominantly observed. Clearly, these results demonstrate that both the oxidized and reduced forms of PrP can yield morphologically similar amyloid fibrils. However, a comparison of the two sigmoidal curves (Fig. 2 B) indicates that reduced PrP has a shorter lag time (tlag) for amyloid formation relative to oxidized PrP (Fig. 2 D), suggesting that disulfide bond reduction accelerates amyloid formation at 2 M GuHCl.
To determine whether or not the disulfide bond is present in the final structure of amyloid fibrils, I next examined the redox states of amyloid fibrils using a thiol-reactive agent, DTNB, according to the Ellman method (26). Here, the amyloid fibrils formed from oxidized or reduced PrP were initially separated from residual monomers by centrifugation at 62,900 × g for 30 min, and subsequently dissociated into constitutive monomers under acidic conditions (6 M guanidine thiocyanate, pH 4). Next, the standard Ellman assay was used to quantify the number of free thiol groups in the individual protein monomers (for more details, see Materials and Methods). As shown in Fig. 2 E, the protein monomer dissociated from reduced amyloid fibrils contained two free thiol groups per molecule, consistent with the number of the cysteine residues in the amino acid sequence of PrP. By contrast, no free thiol groups were detected in the protein monomers dissociated from oxidized amyloid fibrils, indicating that all cysteine residues had formed the intramolecular disulfide bond. These results confirm that the redox states of PrP remained unchanged during structural conversion from monomers to amyloid fibrils in this experiment.
Three potential mechanisms affecting the rate of amyloid formation
At least three mechanisms may underlie the high amyloidogenic propensity of reduced PrP. Fig. 1 B illustrates a simplified amyloid formation pathway from the native state (N) to amyloid fibrils (Am) via an amyloidogenic unfolded state (U), together with three possible mechanisms affecting the overall rate of amyloid formation. The first mechanism assumes that disulfide bond reduction alters the reaction pathway of amyloid formation such that the height of the kinetic barrier is decreased (ΔGN–‡’ < ΔGN–‡, mechanism I). This mechanism can be experimentally tested by comparing the final structures of amyloid fibrils and determining whether the final state of oxidized and reduced proteins is identical (Am) or not (Am′). Strictly speaking, however, a change in the reaction pathway does not always lead to a detectable change in the final structure of amyloid fibrils. Therefore, it is virtually impossible to completely rule out or confirm mechanism I through a structural comparison. The second and third mechanisms respectively assume that disulfide bond reduction affects the free-energy differences between the N and U states (ΔGN–U, mechanism II) and between the U and transition states (ΔG‡–U, mechanism III). As the total height of the kinetics barrier of amyloid formation (ΔGN–‡) is represented by the sum of ΔGN–U and ΔGU–‡, these two values are particularly important with respect to the overall rate of protein aggregation. Mechanisms II and III can be easily tested using simple thermodynamic and kinetic experiments, as described below. In the following sections, I will examine which mechanism contributes predominantly to the strong amyloidogenic propensity of reduced PrP.
Structural effects of disulfide bond reduction on amyloid fibrils
To address whether disulfide bond reduction affects the reaction pathway of amyloid formation (mechanism I), I examined amyloid fibril structures using FTIR spectroscopy and the proteinase K (PK) digestion assay. These assays are widely used to detect structural differences (polymorphisms) of amyloidlike aggregates with good sensitivity (35, 36, 37). As shown in Fig. 3 A, the FTIR spectra and second derivatives of oxidized and reduced amyloid fibrils overlapped completely, indicating a common secondary structure content. The position of the peak bond (1621 cm−1) indicated that both amyloid fibrils were enriched with the intermolecular β-sheet structure (38). Fig. 3 B shows the results of PK-digestion assay for both proteins. Although a marked increase in PK-resistance was observed for both proteins upon the conversion from monomers of amyloid fibrils, no clear difference in the PK digestion pattern was observed in the amyloid forms, indicating that both amyloid fibrils shared a common PK resistant core at the C-terminal residues (27, 29, 31, 39, 40). The observed slight difference in the band intensity (i.e., oxidized amyloid fibrils appeared to produce a more intense band relative to reduced amyloid fibrils) likely reflect a difference in equilibrium stability rather than in structure (see Fig. 4 B). Therefore, disulfide bond reduction does not affect the final structure of amyloid fibrils, at least at the secondary structural level, and the oxidized and reduced proteins seem to use the same reaction pathway for amyloid formation. However, a further study using high-resolution techniques is required to determine whether disulfide bond reduction affects the tertiary and quaternary structure of amyloid fibrils.
Effect on the equilibrium stability of the N state
Next, I performed GuHCl-unfolding experiments to examine whether disulfide bond reduction would affect the equilibrium stability of the N state (mechanism II). The GuHCl-unfolding curves for the monomeric forms of oxidized and reduced PrP were obtained using far-UV circular dichroism (Fig. 4 A). Curve-fitting using a two-state unfolding model indicated that the oxidized protein existed as a 4:6 mixture of the N and U states at 2 M GuHCl, whereas the reduced protein existed as the pure U state at the same concentration of GuHCl, suggesting that disulfide bond reduction decreased the proportion of the N state and simultaneously increased the proportion of the U state. A comparison of the two GuHCl-unfolding curves led to rough estimation that disulfide bond reduction destabilized the N state by a minimum of 3.1 kcal/mol in denaturant-free solution (a precise value was not obtained because reduced PrP precipitated as an amorphous aggregate at low concentrations of GuHCl) (Table 1). A similar destabilizing effect of disulfide bond reduction has been reported in previous publications examining PrP folding (3, 4, 5, 6). Therefore, disulfide bond reduction decreases the equilibrium stability of the N state, suggesting that mechanism II at least partly contributes to the strong amyloidogenic propensity of reduced PrP at 2 M GuHCl.
Table 1.
ΔGox | ΔGred | ΔΔG (ΔGred−ΔGox) | |
---|---|---|---|
Monomer (ΔGN–U) | −3.1 ± 0.1 | <0 | >3.1 |
Amyloid fibril (ΔGAm–U) | −6.0 ± 1.1 | −2.9 ± 0.1 | 3.1 ± 1.1 |
Measured in kcal/mol.
Effect on the kinetic barrier of aggregation
To measure effect of the disulfide bond on the height of the free-energy barrier (ΔG‡–U), I repeated the above kinetic experiment at a higher concentration of GuHCl (3 M), where both oxidized and reduced PrP existed in an almost pure U state (N state: <5%, Fig. 4 A). The rationale behind this experiment is that if a protein exists in a pure U state, then the rate of amyloid formation should reflect the ΔGU–‡ without any contribution from ΔGN–U. Previously, Dutta et al. (41) used this approach to demonstrate that S170N/N174T mutation enhanced the amyloidogenic propensity of PrP mainly by decreasing ΔG‡–U, but not ΔGN–U. Here, I chose the minimum GuHCl concentration required for PrP unfolding because, at higher GuHCl concentrations (>4 M), the reverse reaction (i.e., the dissociation of amyloid fibrils) becomes nonnegligible and thus complicates the kinetics of amyloid formation.
Remarkably, as shown in Fig. 5, A and B, the oxidized and reduced PrP did not differ significantly in terms of tlag under the fully unfolded conditions (3 M GuHCl), indicating that disulfide bond reduction does not affect the rate of amyloid formation when the N state is completely disrupted. In other words, disulfide bond reduction does not affect the ΔG‡–U, thus ruling out mechanism III. This result has an additional implication regarding the structure of the transition state (‡) during amyloid formation. Specifically, the finding that disulfide bond reduction stabilizes ‡ by the same extent as the U state indicates that the two segments containing residues C179 and C214 (i.e., H2 and H3) are not associated in ‡ (for more details, see Fig. 3 in (42)).
Destabilization of the N state drives reduction-induced aggregation
Taken together, the results of the above series of experiments indicate that disulfide bond reduction accelerates amyloid formation mainly by destabilizing the N state (mechanism II). By contrast, the reaction pathway of amyloid formation (mechanism I) and the height of the free-energy barrier separating the U state from the amyloid state (mechanism III) appear to remain unchanged upon disulfide bond reduction. These experiments led me to conclude that disulfide bond reduction enhances the amyloidogenic propensity of PrP mainly by destabilizing the N state.
Effect on the equilibrium stability of amyloid fibrils
The equilibrium stability of amyloid fibrils relative to the U state (ΔGAm–U) is an important parameter both for characterizing the overall folding/misfolding landscape as and for determining whether the disulfide bond is beneficial for the stability of amyloid fibrils. I therefore examined the effect of disulfide bond reduction on ΔGAm–U using the GuHCl-unfolding assay. This assay has been widely used to estimate ΔGAm–U, based on the linear-polymerization model of amyloid formation (28, 43). Because the amyloid fibrils were insufficiently soluble to allow a far-UV CD measurement, in this study, the GuHCl-unfolding curves were determined by measuring ThT fluorescence.
As shown in Fig. 4 B, the reduced and oxidized amyloid fibrils represented the major unfolding transitions in 2–6 M GuHCl and 5–8 M GuHCl, respectively. The lower shift of the unfolding curve clearly indicates that disulfide bond reduction destabilizes the amyloid fibrils and thus increases ΔGAm–U. Although the oxidized amyloid fibrils represented an additional transition at lower GuHCl concentrations (0–2 M) (Fig. 4 B), I ignored this transition in the subsequent analysis. This is because the oxidized PrP monomer exists as an equilibrium between the N and U states at low GuHCl concentrations (1–2.5 M, Fig. 4 A), and thus the GuHCl-unfolding of amyloid fibrils depends not only on ΔGAm–U but also on ΔGN–U. Such complexity can be reduced by ignoring the low GuHCl concentration data. Accordingly, by fitting the GuHCl-unfolding curves of oxidized (only 3–8 M) and reduced (0–8 M) amyloid fibrils to the linear polymerization model, ΔGAm–U was estimated as −6.0 ± 1.1 and −2.9 ± 0.1 kcal/mol, respectively. Therefore, disulfide bond reduction destabilized amyloid fibrils, and increased ΔGAm–U by 3.1 ± 1.1 kcal/mol (Table 1).
Interestingly, the destabilizing effect of the disulfide bond reduction on amyloid fibrils (ΔΔGAm–U = 3.1 ± 1.1 kcal/mol) is very similar to the effect on the N state (ΔΔGN–U > 3.1 kcal/mol), indicating that the decrease in the stabilities of these two states is mainly conferred by an ∼3–4 kcal/mol decrease in the free energy of the reference state (i.e., U state) (Fig. 4 C). Disulfide bond reduction typically increases the entropy of U state by removing conformational constraints imposed by the disulfide bond and leading to a substantial decrease in the free energy (42). The Pace equation estimated that the entropic effect contributes to ∼4 kcal/mol decrease in the free energy of the U state (44), which is reasonably consistent with the ΔΔGAm–U and ΔΔGN–U values. This result indicates that, by decreasing the free energy of the U state without changing the free energies of either the N state or amyloid fibrils, disulfide bond reduction leads to a net destabilization of the two latter states. This in turn implicates that the disulfide bond connecting C179 and C214 is accommodated in a very restricted manner in the N state and amyloid fibrils, such that disulfide bond reduction does not increase the entropy and free energies of these two states.
Author Contributions
R.H. designed and performed all the experiments, analyzed the data, and wrote the manuscript.
Acknowledgments
The author thanks Kazuo Kuwata for use of laboratory analytical instruments, and Enago (https://www.enago.jp) for the English language review.
This work was supported by JSPS KAKENHI grant No. 16J04145.
Editor: James Shorter.
References
- 1.Colby D.W., Prusiner S.B. Prions. Cold Spring Harb. Perspect. Biol. 2011;3:a006833. doi: 10.1101/cshperspect.a006833. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Zahn R., Liu A., Wüthrich K. NMR solution structure of the human prion protein. Proc. Natl. Acad. Sci. USA. 2000;97:145–150. doi: 10.1073/pnas.97.1.145. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Eberl H., Glockshuber R. Folding and intrinsic stability of deletion variants of PrP(121–231), the folded C-terminal domain of the prion protein. Biophys. Chem. 2002;96:293–303. doi: 10.1016/s0301-4622(02)00015-7. [DOI] [PubMed] [Google Scholar]
- 4.Mehlhorn I., Groth D., Prusiner S.B. High-level expression and characterization of a purified 142-residue polypeptide of the prion protein. Biochemistry. 1996;35:5528–5537. doi: 10.1021/bi952965e. [DOI] [PubMed] [Google Scholar]
- 5.Zhang H., Stockel J., Cohen F.E. Physical studies of conformational plasticity in a recombinant prion protein. Biochemistry. 1997;36:3543–3553. doi: 10.1021/bi961965r. [DOI] [PubMed] [Google Scholar]
- 6.Maiti N.R., Surewicz W.K. The role of disulfide bridge in the folding and stability of the recombinant human prion protein. J. Biol. Chem. 2001;276:2427–2431. doi: 10.1074/jbc.M007862200. [DOI] [PubMed] [Google Scholar]
- 7.Jackson G.S., Hosszu L.L., Collinge J. Reversible conversion of monomeric human prion protein between native and fibrillogenic conformations. Science. 1999;283:1935–1937. doi: 10.1126/science.283.5409.1935. [DOI] [PubMed] [Google Scholar]
- 8.Hosszu L.L., Trevitt C.R., Clarke A.R. Conformational properties of β-PrP. J. Biol. Chem. 2009;284:21981–21990. doi: 10.1074/jbc.M809173200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Trevitt C.R., Hosszu L.L., Clarke A.R. N-terminal domain of prion protein directs its oligomeric association. J. Biol. Chem. 2014;289:25497–25508. doi: 10.1074/jbc.M114.566588. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Lee S., Eisenberg D. Seeded conversion of recombinant prion protein to a disulfide-bonded oligomer by a reduction-oxidation process. Nat. Struct. Biol. 2003;10:725–730. doi: 10.1038/nsb961. [DOI] [PubMed] [Google Scholar]
- 11.Herrmann L.M., Caughey B. The importance of the disulfide bond in prion protein conversion. Neuroreport. 1998;9:2457–2461. doi: 10.1097/00001756-199808030-00006. [DOI] [PubMed] [Google Scholar]
- 12.Welker E., Raymond L.D., Caughey B. Intramolecular versus intermolecular disulfide bonds in prion proteins. J. Biol. Chem. 2002;277:33477–33481. doi: 10.1074/jbc.M204273200. [DOI] [PubMed] [Google Scholar]
- 13.Turk E., Teplow D.B., Prusiner S.B. Purification and properties of the cellular and scrapie hamster prion proteins. Eur. J. Biochem. 1988;176:21–30. doi: 10.1111/j.1432-1033.1988.tb14246.x. [DOI] [PubMed] [Google Scholar]
- 14.Stahl N., Baldwin M.A., Prusiner S.B. Structural studies of the scrapie prion protein using mass spectrometry and amino acid sequencing. Biochemistry. 1993;32:1991–2002. doi: 10.1021/bi00059a016. [DOI] [PubMed] [Google Scholar]
- 15.Zako T., Sakono M., Maeda M. Bovine insulin filaments induced by reducing disulfide bonds show a different morphology, secondary structure, and cell toxicity from intact insulin amyloid fibrils. Biophys. J. 2009;96:3331–3340. doi: 10.1016/j.bpj.2008.12.3957. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Devlin G.L., Knowles T.P., MacPhee C.E. The component polypeptide chains of bovine insulin nucleate or inhibit aggregation of the parent protein in a conformation-dependent manner. J. Mol. Biol. 2006;360:497–509. doi: 10.1016/j.jmb.2006.05.007. [DOI] [PubMed] [Google Scholar]
- 17.Maeda R., Ado K., Taniguchi Y. Promotion of insulin aggregation by protein disulfide isomerase. Biochim. Biophys. Acta. 2007;1774:1619–1627. doi: 10.1016/j.bbapap.2007.08.016. [DOI] [PubMed] [Google Scholar]
- 18.Li Y., Gong H., Huang K. Dissecting the role of disulfide bonds on the amyloid formation of insulin. Biochem. Biophys. Res. Commun. 2012;423:373–378. doi: 10.1016/j.bbrc.2012.05.133. [DOI] [PubMed] [Google Scholar]
- 19.Stöhr J., Wu H., DeGrado W.F. A 31-residue peptide induces aggregation of tau’s microtubule-binding region in cells. Nat. Chem. 2017;9:874–881. doi: 10.1038/nchem.2754. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Bhattacharya K., Rank K.B., Sharma S.K. Role of cysteine-291 and cysteine-322 in the polymerization of human tau into Alzheimer-like filaments. Biochem. Biophys. Res. Commun. 2001;285:20–26. doi: 10.1006/bbrc.2001.5116. [DOI] [PubMed] [Google Scholar]
- 21.Cao A., Hu D., Lai L. Formation of amyloid fibrils from fully reduced hen egg white lysozyme. Protein Sci. 2004;13:319–324. doi: 10.1110/ps.03183404. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Yang M., Dutta C., Tiwari A. Disulfide-bond scrambling promotes amorphous aggregates in lysozyme and bovine serum albumin. J. Phys. Chem. B. 2015;119:3969–3981. doi: 10.1021/acs.jpcb.5b00144. [DOI] [PubMed] [Google Scholar]
- 23.Ohhashi Y., Hagihara Y., Goto Y. The intrachain disulfide bond of β(2)-microglobulin is not essential for the immunoglobulin fold at neutral pH, but is essential for amyloid fibril formation at acidic pH. J. Biochem. 2002;131:45–52. doi: 10.1093/oxfordjournals.jbchem.a003076. [DOI] [PubMed] [Google Scholar]
- 24.Li Y., Yan J., Huang K. Disulfide bonds in amyloidogenesis diseases related proteins. Proteins. 2013;81:1862–1873. doi: 10.1002/prot.24338. [DOI] [PubMed] [Google Scholar]
- 25.Honda R.P., Kuwata K. The native state of prion protein (PrP) directly inhibits formation of PrP-amyloid fibrils in vitro. Sci. Rep. 2017;7:562. doi: 10.1038/s41598-017-00710-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Winther J.R., Thorpe C. Quantification of thiols and disulfides. Biochim. Biophys. Acta. 2014;1840:838–846. doi: 10.1016/j.bbagen.2013.03.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Bocharova O.V., Breydo L., Baskakov I.V. Synthetic prions generated in vitro are similar to a newly identified subpopulation of PrPSc from sporadic Creutzfeldt-Jakob disease. Protein Sci. 2005;14:1222–1232. doi: 10.1110/ps.041186605. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Narimoto T., Sakurai K., Goto Y. Conformational stability of amyloid fibrils of β2-microglobulin probed by guanidine-hydrochloride-induced unfolding. FEBS Lett. 2004;576:313–319. doi: 10.1016/j.febslet.2004.09.024. [DOI] [PubMed] [Google Scholar]
- 29.Cobb N.J., Sönnichsen F.D., Surewicz W.K. Molecular architecture of human prion protein amyloid: a parallel, in-register β-structure. Proc. Natl. Acad. Sci. USA. 2007;104:18946–18951. doi: 10.1073/pnas.0706522104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Bocharova O.V., Breydo L., Baskakov I.V. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc) J. Mol. Biol. 2005;346:645–659. doi: 10.1016/j.jmb.2004.11.068. [DOI] [PubMed] [Google Scholar]
- 31.Singh J., Udgaonkar J.B. Dissection of conformational conversion events during prion amyloid fibril formation using hydrogen exchange and mass spectrometry. J. Mol. Biol. 2013;425:3510–3521. doi: 10.1016/j.jmb.2013.06.009. [DOI] [PubMed] [Google Scholar]
- 32.Milto K., Michailova K., Smirnovas V. Elongation of mouse prion protein amyloid-like fibrils: effect of temperature and denaturant concentration. PLoS One. 2014;9:e94469. doi: 10.1371/journal.pone.0094469. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Kocisko D.A., Come J.H., Caughey B. Cell-free formation of protease-resistant prion protein. Nature. 1994;370:471–474. doi: 10.1038/370471a0. [DOI] [PubMed] [Google Scholar]
- 34.Adachi M., So M., Goto Y. Supersaturation-limited and unlimited phase transitions compete to produce the pathway complexity in amyloid fibrillation. J. Biol. Chem. 2015;290:18134–18145. doi: 10.1074/jbc.M115.648139. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Bocharova O.V., Makarava N., Baskakov I.V. Annealing prion protein amyloid fibrils at high temperature results in extension of a proteinase K-resistant core. J. Biol. Chem. 2006;281:2373–2379. doi: 10.1074/jbc.M510840200. [DOI] [PubMed] [Google Scholar]
- 36.Jones E.M., Surewicz W.K. Fibril conformation as the basis of species- and strain-dependent seeding specificity of mammalian prion amyloids. Cell. 2005;121:63–72. doi: 10.1016/j.cell.2005.01.034. [DOI] [PubMed] [Google Scholar]
- 37.Hill A.F., Joiner S., Collinge J. Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain. 2003;126:1333–1346. doi: 10.1093/brain/awg125. [DOI] [PubMed] [Google Scholar]
- 38.Zandomeneghi G., Krebs M.R., Fändrich M. FTIR reveals structural differences between native β-sheet proteins and amyloid fibrils. Protein Sci. 2004;13:3314–3321. doi: 10.1110/ps.041024904. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Lu X., Wintrode P.L., Surewicz W.K. Beta-sheet core of human prion protein amyloid fibrils as determined by hydrogen/deuterium exchange. Proc. Natl. Acad. Sci. USA. 2007;104:1510–1515. doi: 10.1073/pnas.0608447104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Tycko R., Savtchenko R., Baskakov I.V. The α-helical C-terminal domain of full-length recombinant PrP converts to an in-register parallel β-sheet structure in PrP fibrils: evidence from solid state nuclear magnetic resonance. Biochemistry. 2010;49:9488–9497. doi: 10.1021/bi1013134. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Dutta A., Chen S., Surewicz W.K. The effect of β2-α2 loop mutation on amyloidogenic properties of the prion protein. FEBS Lett. 2013;587:2918–2923. doi: 10.1016/j.febslet.2013.07.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Wedemeyer W.J., Welker E., Scheraga H.A. Disulfide bonds and protein folding. Biochemistry. 2000;39:4207–4216. doi: 10.1021/bi992922o. [DOI] [PubMed] [Google Scholar]
- 43.Baldwin A.J., Knowles T.P., Dobson C.M. Metastability of native proteins and the phenomenon of amyloid formation. J. Am. Chem. Soc. 2011;133:14160–14163. doi: 10.1021/ja2017703. [DOI] [PubMed] [Google Scholar]
- 44.Pace C.N., Grimsley G.R., Barnett B.J. Conformational stability and activity of ribonuclease T1 with zero, one, and two intact disulfide bonds. J. Biol. Chem. 1988;263:11820–11825. [PubMed] [Google Scholar]